APOGEE THERAPEUTICS acquired by ABBVIE

Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets

DHCare has entered into an agreement to acquire Ottobock's Human Mobility business, which specializes in manual and power wheelchairs, as well as pediatric mobility solutions. This transaction is part of Ottobock's strategy to refocus its resources on its core, high-growth businesses, including prosthetics, neuro-orthotics, and exoskeletons

CordenPharma, backed by private equity firm Astorg, entered into an agreement to acquire AmbioPharm, a US-based CDMO specializing in complex peptide APIs with manufacturing sites in the United States and China

The acquisition of a 51% controlling interest in Laboratoire Nutergia by 3i presents a primary leveraged buyout transaction designed to transition a mature, founder-led enterprise into an institutionalized platform capable of capturing pan-European market share

The closing of this oversubscribed 86.6 million dollar Series B financing represents a structural capitalization event designed to transition Ona Therapeutics into a clinical-stage oncology platform and fund operations through its primary clinical data readouts

Motion Equity Partners has acquired a majority stake in Polaris, a leading manufacturer of omega-3 concentrates, from Demea Agro, which had invested in the company three years ago. This transaction is part of a broader strategy to drive external growth and international expansion, with ambitious plans to establish a US-based industrial site and double in size within the next five years

Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation

Rantum Private Equity Fund II has successfully finalized the acquisition of a majority stake in the share capital of the target, marking its seventh investment from the current fund. This strategic transaction represents a pivotal step in the acquirer’s objective to establish a dominant position in the high-precision medical technology sector, specifically targeting the resilient demand for minimally invasive surgery

The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market

UCB has entered into a definitive agreement to acquire Neurona Therapeutics, a maneuver designed to fundamentally reinforce the group’s leadership in the global epilepsy market. The strategic rationale for this transaction centers on a "regeneration-acceleration" play, merging the target's industry-leading stem cell platform with the group’s extensive therapeutic expertise and global commercial infrastructure